1) Today’s News Headlines
Hims & Hers abruptly stopped offering a compounded “Wegovy pill” copy after FDA scrutiny and legal pressure—signaling a tougher line on mass-marketed, non‑FDA‑approved GLP‑1 copies. (apnews.com)
Meanwhile, Novo Nordisk’s FDA‑approved Wegovy pill is now broadly available in the U.S., expanding non-injection options for obesity treatment. (washingtonpost.com)
2) Today’s Top Stories (past 24 hours)
Hims & Hers Drops Its “Wegovy Pill” Knockoff After FDA Warning
Hims & Hers said it would stop offering a compounded oral semaglutide product positioned as an alternative to Novo Nordisk’s newly launched Wegovy pill. Reports describe escalating regulatory pressure (including FDA scrutiny and potential referral for enforcement) alongside legal threats from Novo Nordisk. (apnews.com)
Why it matters: If you’re shopping for cheaper GLP‑1s online, this is a reminder: “compounded” doesn’t mean “FDA‑approved,” and access can change overnight.
Source: AP (apnews.com)
FDA’s GLP‑1 Compounding Policy: The Window Has Been Closing
The FDA has been steadily tightening enforcement discretion timelines as national GLP‑1 supply stabilizes, emphasizing legal restrictions on compounding “essentially copies” of FDA‑approved drugs—especially once a shortage is considered resolved. (fda.gov)
Why it matters: Compounded semaglutide/tirzepatide availability may continue to shrink; patients should plan continuity of care (and refills) with clinicians rather than relying on gray-market substitutes.
Source: U.S. FDA (Drug Safety & Availability) (fda.gov)
Wegovy Pill: The First Widely Available Oral GLP‑1 Option for Weight Loss
Novo Nordisk’s once‑daily Wegovy pill has launched nationally, with reported broad pharmacy availability and cash pricing that scales by dose. (washingtonpost.com)
Novo also highlighted phase 3 trial results (OASIS 4) and positioned the product as an FDA‑reviewed alternative amid the compounding debate. (prnewswire.com)
Why it matters: For needle‑averse patients, the oral option could reduce a major barrier—just remember oral GLP‑1s can have specific administration instructions and similar GI side effects.
Source: The Washington Post (washingtonpost.com)
3) Deep Dive (Weekend Edition): Mindset & Strategy
The “Consistency Floor” Plan: How to Keep Losing (or Maintaining) When Life Gets Messy
Most sustainable weight loss isn’t built on perfect weeks—it’s built on non‑negotiables you can keep doing when motivation is low, travel hits, stress spikes, or your schedule explodes. This is especially important if you’re on a GLP‑1: appetite may be lower, but routines still drive outcomes (protein, steps, sleep, and meal structure remain the boring basics that work).
Build your Consistency Floor (pick 3–5):
- Protein anchor at 2 meals/day
Choose any two meals where you reliably hit a protein “minimum.” This can reduce mindless grazing and helps preserve lean mass during weight loss. Examples: Greek yogurt + berries; eggs + cottage cheese; chicken/tofu salad; protein-forward chili. - A 10–15 minute walk after one meal
Post-meal movement is a low-friction habit that supports glucose control and makes “exercise” feel more doable on hard days. - A “default” grocery list
When decision fatigue is high, you don’t need new recipes—you need autopilot. Keep a short list you can reorder weekly: ready-to-eat veggies, fruit, a protein you like, a convenient carb (rice, potatoes, wraps), and a sauce/spice you enjoy. - One “calm meal” you can always tolerate (especially on GLP‑1s)
If nausea/fullness flares, forcing large meals can backfire. Have a gentle option ready: soup + crackers, yogurt, a small smoothie, oatmeal with protein, or broth-based meals. - A hard stop on “weekend all-or-nothing” thinking
Instead of “I blew it,” use: “Next decision is the comeback.” If you overate at lunch, the plan isn’t punishment—it’s simply dinner that supports your goals.
Myth-busting (kindly):
– Myth: “If I can’t do my full workout, it’s not worth it.”
Reality: A small walk, a short bodyweight circuit, or even just hitting steps keeps the identity and momentum alive. The habit is the win.
Try this today (5-minute reset):
Write your Consistency Floor on a sticky note. If your day goes sideways, your only job is to hit those 3–5 items. That’s it.
4) Quick Hits
- Hims’ rapid reversal is a case study in why “cheap GLP‑1s online” can be unstable—and why continuity planning matters. (businessinsider.com)
- The FDA continues emphasizing that compounded drugs are not FDA‑approved and face restrictions when they are “essentially copies” of commercial products. (fda.gov)
- If you’re considering switching from compounded to branded GLP‑1s, ask your clinician about dose conversions, titration schedules, and side-effect management (don’t DIY).
- Oral Wegovy availability may shift the market conversation from “shots vs nothing” to “shots vs pills” for eligible patients. (washingtonpost.com)
- If you struggle with nausea on GLP‑1s: smaller meals, slower eating, lower-fat choices, and hydration timing can help—coordinate changes with your prescriber.
- Reminder: supply at the national level can be different from what your local pharmacy has—plan refills early. (fda.gov)
5) By The Numbers
40.3% — the prevalence of obesity among U.S. adults during August 2021–August 2023 (NHANES).
What it means: Obesity remains common—and stable at a high level—highlighting the need for both prevention and effective long-term treatment options (lifestyle, medication, surgery, and combinations). (cdc.gov)
Why you should care: If you’ve felt alone or blamed yourself, the data reinforces that this is a widespread, complex chronic disease—not a personal failure. (cdc.gov)
6) Ask The Community
What’s on your Consistency Floor—the 3–5 habits you can keep even on your worst weeks?
7) Tomorrow’s Preview
Medication Monday: A practical guide to navigating GLP‑1 access in 2026—what “compounded” really means now, questions to ask your prescriber, and ways to reduce side effects while protecting muscle during weight loss.